Tom Nolan’s research reviews—20 April 2023

Blood pressure management (tailor’s version)Using genetic, biomarker, and other individual characteristics to come up with a tailor-made treatment plan sounds a bit like, well, going to a tailor. When it comes to key decisions about our health, we might well prefer a bespoke outfit (and some will be able to afford one), but, looking at healthcare systems right now, most people are lucky if they can find something that’s good enough off the peg. A randomised, double blind, crossover trial set in Sweden explored the potential for personalised therapy in people with grade 1 hypertension at low risk for cardiovascular events. Participants took one of four antihypertensives (lisinopril, candesartan, hydrochlorothiazide, or amlodipine) for a month or longer, then, after a washout period, switched to the next one, and repeated this until they’d taken all four. Blood pressure response varied considerably between participants—overall the researchers found that a personalised approach could…
Read Original Article: Tom Nolan’s research reviews—20 April 2023 »